Optiscan has been featured in Stockhead's Long Shortz where Optiscan CEO Dr. Camile Farah spoke with Tylah Tully to discuss the early commencement of stage two of the company’s head and neck cancer study.

He also unpacks why it’s an important milestone for its FDA submissions, and the key catalysts investors should be watching as Optiscan advances toward regulatory approval.

Watch the full video here.